Loading
AbCellera Biologics Inc. Stock: price and insider trades · United States
3 insiders bought €1.3M of shares over the last 90 days, the latest by Hayden Michael R, filed 24 Aug 2026.
Insider Decl.
105
Thresholds
n/a
Buy Volume
€80M
43 ops. · all time
Sell Volume
€213M
9 ops. · all time
Who traded when
BuySaleJohn S. Montalbano4 buys
Thermopylae Holdings Ltd.3 buys
Andrew Booth2 buys
Michael R. Hayden2 buys
Since the insiders bought
- -9.0%Entry US$12.50 · Close 22 Oct 2026 US$11.37
- -5.3%Entry US$12.01 · Close 22 Oct 2026 US$11.37
- +1.5%Entry US$11.20 · Close 22 Oct 2026 US$11.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate AbCellera Biologics Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$16.82.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,236 of 26,250 companies
29.9
score / 100
Value23
Quality36
FCF yld-4.4%
Earn yld-3.7%
EV/EBITDA·
ROE-17%
Gross mgn38%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.24
Analyst consensus
11 analystsStrong buy
US$9.00Target US$16.82(+37%)US$30.00
Income statement
RevenueUS$75.1M
Gross profitUS$28.8M38% margin
EBITDA-US$174.4M-232% margin
Net income-US$146.4M-248.8% margin
Valuation
PER (forward)-16.1x
P/Book4.2x
Beta1.41
Balance sheet & cash
Market capUS$4B
Total debtUS$143.2M
Free Cash Flow-US$174.1M
Debt / Equity15%
Profitability & ownership
ROE-17.3%
ROA-10.4%
% insiders21.7%
% institutions36.7%
Last declaration on 24 August 2026
Declarations105 total
53,613 shares@ US$10.640.014% mcap6.6% of flowCommon SharesSEC:0001628280-26-058684:0
Canonical exit: 22 Nov 2026 (T+90)
10,000 shares@ US$11.030.0026% mcap11.3% of flowCommon SharesSEC:0001834423-26-000008:0
Canonical exit: 16 Nov 2026 (T+90)
46,387 shares@ US$10.370.012% mcap5.7% of flowCommon SharesSEC:0001628280-26-057007:0
Canonical exit: 10 Nov 2026 (T+90)
37,200 shares@ US$10.320.0092% mcap1.2% of flowCommon SharesSEC:0001834411-26-000008:0
Canonical exit: 12 Nov 2026 (T+90)
50,000 shares0Common SharesSEC:0001628280-26-056653:0
250,000 shares@ US$0.190.0012% mcap0.2% of flowCommon SharesSEC:0001834411-26-000006:0
38,000 shares@ US$3.440.1% of flowCommon SharesSEC:0001834449-26-000004:0
Canonical exit: 28 May 2026 (T+90)
177,457 shares@ US$3.270.4% of flowCommon SharesSEC:0001834449-26-000002:0
Canonical exit: 27 May 2026 (T+90)
42,600 shares@ US$3.420.5% of flowCommon SharesSEC:0001834411-26-000004:0
Canonical exit: 28 May 2026 (T+90)
225,000 shares0Common SharesSEC:0001834449-25-000004:0
50,000 shares@ US$3.569218.3% of flowCommon SharesSEC:0001834423-25-000004:0
Canonical exit: 24 Feb 2026 (T+90)
343,631 shares@ US$2.160.5% of flowCommon SharesSEC:0001628280-25-012154:0
Canonical exit: 9 Jun 2025 (T+90)
25,000 shares@ US$2.306.3% of flowCommon SharesSEC:0001628280-25-011750:0
Canonical exit: 8 Jun 2025 (T+90)
60,000 shares@ US$2.342815.4% of flowCommon SharesSEC:0001628280-25-011254:0
Canonical exit: 4 Jun 2025 (T+90)
286,000 shares0Common SharesSEC:0001628280-24-050097:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001628280-24-049327:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001628280-24-041217:0
283,516 shares@ US$2.610.5% of flowCommon SharesSEC:0001628280-24-038829:0
Canonical exit: 27 Nov 2024 (T+90)
83,334 shares@ US$0.1880.1% of flowCommon SharesSEC:0001628280-24-029675:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001628280-24-026338:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001703057-24-000026:0
210,000 shares0Common SharesSEC:0001703057-23-000049:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001703057-23-000044:0
20,000 shares@ US$4.6410.2% of flowCommon SharesSEC:0001703057-23-000042:0
Canonical exit: 4 Feb 2024 (T+90)
10,000 shares@ US$4.463.2% of flowCommon SharesSEC:0001703057-23-000042:1
Canonical exit: 6 Feb 2024 (T+90)
25 of 105 declarations
About AbCellera Biologics Inc.
On December 15, 2020, 5 filers at AbCellera Biologics Inc. bought on the same day for EUR 51,394,215, including EUR 49,387,202 for Peter Thiel (Director), the largest purchase in the record. Thermopylae Holdings Ltd. follows with EUR 8,691,874 on May 12, 2022 and EUR 2,608,332 on November 11, 2021. In all there are 43 purchases worth EUR 79.8 million (median EUR 329,248).
Sales are fewer, 9, but heavier: EUR 213.2 million, with a median of EUR 20,932,516. On June 9, 2021, Thermopylae Holdings Ltd. sold for EUR 110,433,413, Andrew Booth (Chief Financial Officer) for EUR 25,119,019 and Veronique Lecault (Chief Operating Officer) for EUR 20,932,516. Purchases are 83% of open-market trades across 104 filings from 12 filers, with 30 option exercises.
Read moreShow less
This US healthcare and pharma company has a market capitalisation of USD 3.87 billion, and insiders hold 21.7% of it. Annual volume falls from 31 filings in 2021 to 5 in 2025. In the last twelve months: 11 filings, 8 of them purchases and no sale. Publication takes a median of 2 days. For 39 purchases a 90-day result is stored: a median of --2.3%, with 49% of results positive, recorded past results and not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
